Accordingly, HSPA5 downregulation or silencing increased the sensitivity of glioma cells to various chemotherapeutic agents, such as TMZ, 5-fluorouracil, irinotecan, etoposide, and cisplatin [51,52]. The gene discussed is HSPA5; the disease is central nervous system cancer.